Market News & Trends
Metrics Contract Services Appoints Commercial Manufacturing BD Lead
Metrics Contract Services, a full-service contract development and manufacturing organization (CDMO) in novel oral solid dose (OSD) products, has appointed Kim Black-Washington as Senior Business…
Viridian Therapeutics Submits IND Application for VRDN-002 to the US FDA
Viridian Therapeutics, Inc. recently announced the submission of an investigational new drug (IND) application to the US FDA for VRDN-002, a humanized monoclonal antibody that…
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Cullinan Oncology, Inc. recently announced the US FDA has granted Breakthrough Therapy Designation for CLN-081 for the treatment of patients with locally advanced or metastatic…
TCR² Therapeutics & Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies
TCR2 Therapeutics Inc. and Arbor Biotechnologies recently announced the two companies have entered into a strategic research collaboration and non-exclusive license agreement focused on the…
Centogene’s CentoCloud Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World
Centogene N.V. recently announced the global release of CentoCloud, a SaaS platform enabling decentralized analysis, interpretation, and reporting of genomic variants linked to rare diseases.…
Ovid Therapeutics Expands Epilepsy Franchise With Novel KCC2 Activators
Ovid Therapeutics Inc. recently announced the company has entered into an exclusive license agreement with AstraZeneca for a library of early stage small molecules targeting…
Spero Therapeutics Announces FDA Acceptance & Priority Review of NDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
Spero Therapeutics, Inc. recently announced the US FDA has granted Priority Review designation and confirmed the acceptance for substantive review of the New Drug Application…
US FDA Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children
Immix Biopharma, Inc. recently announced the US FDA has granted Rare Pediatric Disease (RPD) designation for IMX-110 for the treatment of a life-threatening form of…
FDA Approves First Pill to Treat COVID After Pfizer's Oral Medication Reduced Hospitalizations by 88% in Key Study
US health regulators recently authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst…
Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden
Atossa Therapeutics, Inc. recently announced it has initiated enrollment of its Phase 2 clinical study of oral Z-Endoxifen in Sweden. Participants in the study will…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….